報價延遲最少15分鐘:2026/11/04 17:03 EST
盤後時段
|
||||
|
65.98 
|
|
|
常規時段 (已結束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
66
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-5.62/-4.92
|
|
企業價值
209.41M
|
| 資產負債 |
|
每股賬面淨值
14.69
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
19.39M
|
|
每股收益
0.38
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includesSGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease andother rare keratosis-related indications such as PC, PPK and Olmsted. It generates the majority of its revenue from the United States. |
